Spain's RP system has cut prices 40% so far

The most recent Bulletin released by the trade association Farmaindustria on the Spanish Pharmaceutical market analyzes the impact  of the country's new Order of Reference Prices for drugs, which came  into force in early March this year.

One of the main conclusions of this determines that, if pharmaceutical  companies were now to sell the medicines included in the Reference  Price System, at the prices these products had in late 2006 (before the  first of the orders of the new Reference Price System came into force),  their income in 2009 would be improved by some 1.1 billion euros ($1.39  billion) to what they will currently achieve.

The average decrease of the price of medicines under the RPS from 2006  up to now has reached 40%. Therefore, and according to these  estimations, the total public pharmaceutical expenditure savings  associated with the current RPS could reach 1.2 billion euros in 2009.